Sugi Predict

Sugi Predict / Compounds / SCHEMBL259386

SCHEMBL259386

SCHEMBL259386

Cc1cccc(N2C(=O)c3ccccc3C2=O)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.67
▸ KMT2A Q03164 4/20 0.67
▸ GAA P10253 3/20 0.67
▸ CASP6 P55212 1/20 0.67
▸ L3MBTL1 Q9Y468 2/20 0.63
▸ USP2 O75604 1/20 0.63
▸ KEAP1 Q14145 1/20 0.63
▸ NFE2L2 Q16236 1/20 0.63
▸ HSP90AA1 P07900 2/20 0.61
▸ MGLL Q99685 1/20 0.61
▸ MAPK1 P28482 1/20 0.60
▸ ALDH1A1 P00352 6/20 0.59
▸ HTT P42858 2/20 0.59
▸ HPGD P15428 2/20 0.59
▸ PKM P14618 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ NR1H3 Q13133 1/20 0.57
▸ SCN2A Q99250 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30777591 1.00 MEN1 (0.67) MEN1KMT2AGAACASP6L3MBTL1
SCHEMBL30758580 1.00 MEN1 (0.67) MEN1KMT2AGAACASP6L3MBTL1
SCHEMBL13084656 0.87 MEN1 (0.70) MEN1KMT2AGAACASP6L3MBTL1
SCHEMBL13084695 0.86 KMT2A (0.65) MEN1KMT2AGAACASP6L3MBTL1
SCHEMBL725608 0.86 NR1H3 (0.67) MEN1KMT2AGAAMGLLALDH1A1
SCHEMBL13084814 0.84 ALDH1A1 (0.64) MEN1KMT2AGAACASP6L3MBTL1
SCHEMBL10027194 0.84 MAPK1 (0.56) MEN1KMT2AGAACASP6L3MBTL1
SCHEMBL30792888 0.84 GRM5 (0.62) MEN1KMT2AHSP90AA1ALDH1A1ADORA2A
SCHEMBL11466089 0.84 HSP90AA1 (0.66) MEN1KMT2AGAACASP6L3MBTL1
SCHEMBL5604859 0.84 GRM5 (0.62) MEN1KMT2AHSP90AA1ALDH1A1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239977-A1 SOLVENT-RESISTANT SELF-CROSSLINKED POLY(ETHER IMIDE)S VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2024-07-18 — — US disclosed
CN-117466799-A Preparation method of N-substituted phthalimide compound 西北师范大学 2024-01-30 — — CN disclosed
US-9550742-B2 11-OXO-10,11-dihydrodibenzo[B,F][1,4]thiazepine S-oxide derivatives and their use as dopamine D2 receptor antagonists THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2017-01-24 — — US disclosed
US-20160176831-A1 11-OXO-10,11-DIHYDRODIBENZO[B,F][1,4]THIAZEPINE S-OXIDE DERIVATIVES AND THEIR USE AS DOPAMINE D2 RECEPTOR ANTAGONISTS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2016-06-23 — — US disclosed
US-8796365-B2 Thermoplastic molding materials comprising organic black pigments BASF SE (DE) 2014-08-05 — — US disclosed
US-8449898-B2 Fungicidal mixtures E I DU PONT DE NEMOURS AND COMPANY (US) 2013-05-28 — — US disclosed
US-8449898-B2 Fungicidal mixtures E I DU PONT DE NEMOURS AND COMPANY (US) 2013-05-28 — — US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 — — US disclosed
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 — — US disclosed
WO-2011121062-A1 COMPOSITION FOR THE TREATMENT OF PERIODONTITIS AND OTHER INFLAMMATORY INFECTIOUS DISEASES VOCKNER HELMUT (AT) 2011-10-06 — — WO disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 — — US disclosed
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 — — US disclosed
WO-2009055514-A2 FUNGICIDAL MIXTURES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2009-04-30 — — WO disclosed
US-20090076229-A1 Imide-naphthoxazine copolymer SEKISUI CHEMICAL CO., LTD. (JP) 2009-03-19 — — US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 — — US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 — — US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 — — US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 — — US disclosed
US-5234946-A Anticholesterol, antilipemic BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-08-10 — — US disclosed
EP-0395768-A1 SUBSTITUTED ALLYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE BANYU PHARMACEUTICAL CO., LTD. (JP) 1990-11-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A MEN1 3330/4885KMT2A 1722/4885GAA 1781/4885
US-20100137585-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A MEN1 3330/4885KMT2A 1722/4885GAA 1781/4885
US-20160176831-A1 11-OXO-10,11-DIHYDRODIBENZO[B,F][1,4]THIAZEPINE S-OXIDE DERIVATIVES AND THEIR USE AS DOPAMINE D2 RECEPTOR ANTAGONISTS DRD2, TSHR, GRIN2B MEN1 4429/4885KMT2A 3137/4885GAA 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.